NCT07415668 Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning
| NCT ID | NCT07415668 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Metastases to Brain |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-05-08 |
| Primary Completion | 2029-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-05-08 with a primary completion date of 2029-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
With this project, the study group wants to investigate whether a postoperative navigated transcranial magnetic stimulation (nTMS) motor map can improve stereotactic radiosurgery (SRS) planning in patients who underwent resection for a brain metastasis near the primary motor cortex. Specifically, the map could allow for more precise location of motor eloquent tissue, thereby minimizing the radiation dose on these areas while preserving high radiation dose on target tissue (i.e. tumor cells).
Eligibility Criteria
Inclusion Criteria: 1. Informed consent 2. Age ≥ 18 years 3. Cerebral metastasis within or adjacent to the primary motor cortex (≤10 mm) 4. Resection of tumor 5. Eligible for and planned to undergo postresection radiosurgery at Inselspital Bern Exclusion Criteria: 1. Contraindication to TMS (e.g. Cochlear Implant, other metallic or electrical implants, excluding teeth and post craniotomy, Meniere's disease, pacemaker, deep brain stimulation electrodes, refractory convulsion, symptomatic tinnitus, depression diagnosed by a specialist, psychosis) 2. Prior cerebral radiation therapy within the affected precentral gyrus/affecting the planned SRS plan 3. Planned whole brain radiotherapy 4. Second lesion within 2 cm ipsilateral in the primary motor cortex 5. Infection or difficulties in wound healing within the last two weeks prior inclusion 6. Pregnancy
Frequently Asked Questions
Who can join the NCT07415668 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastases to Brain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07415668 currently recruiting?
Yes, NCT07415668 is actively recruiting participants. Visit ClinicalTrials.gov or contact Insel Gruppe AG, University Hospital Bern to inquire about joining.
Where is the NCT07415668 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT07415668 clinical trial?
NCT07415668 is sponsored by Insel Gruppe AG, University Hospital Bern. The trial plans to enroll 30 participants.